肺癌抗体药物复合体的全球市场:市场机会，专利，价格，临床试验相关洞察(2030年)

全球肺癌抗体-药物偶联物市场：市场机会、专利、定价和临床试验洞察（2030 年）报告结果和亮点

• 研究方法
• 全球肺癌抗体-药物偶联物市场机会：20 亿美元
• 全球及地区趋势
• 已获得商业批准的肺癌抗体-药物偶联物（按品牌名称、公司和适应症划分）
• 已核准的肺癌抗体-药物偶联物的专利、剂量和价格分析
• 临床试验中肺癌抗体-药物偶联物的洞察：120 种药物偶联物
• 肺癌抗体-药物偶联物临床试验洞察：按公司、国家、适应症和阶段
• 癌症抗体-药物偶联物开发平台（按公司）

肺癌治疗对抗体-药物偶联物的需求及本报告的意义

肺癌是全球最具挑战性的癌症之一，发病率和死亡率都很高。手术、化疗和放疗等传统治疗方法已被广泛应用，但长期疗效往往不理想，尤其是在晚期和转移性病例中。因此，对更特异性和更有效治疗方法的需求推动了新型疗法的发展，例如抗体-药物偶联物 (ADC)，它将抗体的特异性与化疗的强效抗癌活性相结合。抗体药物偶联物旨在优先攻击癌细胞，从而最大程度地减少对正常组织的损害并降低全身毒性，与传统疗法相比具有显着优势。随着肺癌的分子和遗传复杂性不断演变，抗体偶联药物 (ADC) 被认为是提高小细胞肺癌 (SCLC) 和非小细胞肺癌 (NSCLC) 患者存活率的关键。

本报告对肺癌抗体偶联药物市场进行了深入分析，为利益相关者提供了有关当前临床试验、创新技术以及定义该市场的关键公司的重要资讯。报告揭示了关键的临床试验结果，监测了有前景的药物的进展，并探索了推动该市场发展的合作机会。

本报告包​​含的肺癌抗体偶联药物临床试验洞察

本报告的一大亮点是全面讨论了肺癌抗体偶联药物的当前和已完成的临床试验。报告概述了临床试验阶段、地区和赞助公司，并深入分析了抗体偶联药物的临床定位。例如，针对 B7-H3 的抗体药物偶联物 ifinatamab deruxtecan (i-DXd) 目前正在进行广泛期小细胞肺癌 (SCLC) 的临床试验。本报告详细讨论了研究目标，例如评估该药物对总存活期和缓解率的影响，这些目标可用于指导临床决策。

此外，我们也展示了这些试验的地理分布，展现了肺癌抗体-药物偶联物开发的全球性。我们也探讨了正在研究的适应症，并重点介绍了各种抗体-药物偶联物对哪些肺癌亚型有效。本报告不仅提供了临床阶段数据，还提供了关键的试验结果，准确概述了抗体-药物偶联物在肺癌治疗中的开发情况。

技术平台、合作与协议

抗体-药物偶联物的成功在很大程度上取决于用于开发和提供此类疗法的技术平台。本分析检视了顶级製药公司成功开发肺癌抗体-药物偶联物所使用的尖端平台。例如，第一三共的DXd平台以其可裂解连接子、拓朴异构酶I抑制剂有效载荷和高活性细胞毒药物的整合而闻名。他为Enhertu和Datroway的研发做出了贡献，这些药物已被证明对HER2和EGFR突变的非小细胞肺癌（NSCLC）有效。

本报告也检视了大型製药公司之间日益增多的合作，例如默克公司与第一三共公司合作开发针对免疫检查点靶点（例如SCLC中的B7-H3）的抗体-药物偶联物。此类合作对于将抗体-药物偶联物推向临床并使其更接近批准至关重要。透过研究这些合作和技术平台，本报告清楚地描绘了推进抗体-药物偶联物开发的先进策略。

活跃于肺癌治疗研发的主要公司

本报告全面分析了开发基于抗体-药物偶联物的肺癌疗法的主要製药和生物技术公司。抗体-药物偶联物开发的主要公司包括阿斯特捷利康、第一三共、辉瑞和百时美施贵宝。领先的公司正在开发针对不同肿瘤抗原（例如 HER2、TROP-2 和 B7-H3）的有前景的抗体-药物偶联物产品线，这些抗原在肺癌治疗中发挥着重要作用。

本报告重点介绍这些公司正在进行的研究活动，包括提高抗体-药物偶联物的强度和特异性。透过分析这些行业领导者，本报告揭示了围绕抗体-药物偶联物开发的竞争动态，并深入了解哪些公司正在引领肺癌治疗的进步。

一份关于抗体-药物偶联物在肺癌治疗中未来发展方向的报告。

本报告阐明了抗体-药物偶联物在肺癌治疗中的未来前景，以及未来的趋势和技术将如何定义市场。抗体-药物偶联物越来越多地与其他疗法（例如免疫检查点抑制剂和抗血管生成药物）联合使用。这种方法的目标是最大限度地提高抗体-药物偶联物的治疗指数，并对抗患者可能出现的抗药性机制。

本报告也预测了更个人化的治疗方法的趋势，其中抗体-药物偶联物旨在针对个别患者中普遍存在的特定基因突变或肿瘤抗原。这是评估patritumab deruxtecan（一种针对HER3的抗体药物偶联物）的临床试验的模式，该药物专门针对具有特定EGFR突变的NSCLC患者。这些趋势表明，抗体-药物偶联物不仅可以用作单一疗法，还可以成为更全面、多组分治疗方案的一部分。

透过回顾趋势和方向，本报告展示了抗体-药物偶联物在肺癌治疗中的未来前景，并为这一快速发展的治疗领域的相关利益相关者提供了有用的建议。

目录

第1章 肺癌抗体药物复合体的简介

第2章 肺癌的标靶治疗的抗体药物复合体

• 肺癌的抗体药物复合体的应用
• 抗体药物复合体的优点
• 抗体药物复合体和传统的治疗方法的比较
• 肺癌抗体药物复合体联合治疗

第3章 肺癌抗体药物复合体的世代

• 抗体药物复合体- 演进
• 新一代抗体药物复合体的展望

第4章 市售已通过核准的肺癌抗体药物复合体(品牌名，公司，各适应症)

第5章 全球肺癌抗体药物复合体市场展望

• 目前市场Scenario
• 肺癌抗体药物复合体的全球市场趋势与开发
• 未来的成长的道

第6章 全球肺癌抗体药物复合体的调查与市场趋势(各地区)

• 美国
• 中国
• 欧洲
• 日本
• 韩国

第7章 已批准肺癌抗体药物复合体- 专利，剂量，价格分析

• Enhertu
• Sacituzumab Tirmotecane
• Datroway
• Emrelis
• 曲妥珠单抗 Brezetecan

第8章 肺癌抗体药物复合体的临床试验概要

• 各期
• 各适应症
• 各企业
• 各快速通道和孤儿药状态
• 各国

第9章 有关肺癌抗体药物复合体的临床试验的全球的洞察(企业，国家，适应症，各期)

• 研究
• 前临床
• 第一阶段
• 第一/二阶段
• 第二阶段
• 第二/三阶段
• 第三阶段
• 登记

第10章 上市的癌症抗体药物复合体的临床试验:企业，国家，适应症，各期

第11章 各企业癌症抗体药物复合体开发平台

第12章 全球肺癌抗体药物复合体市场动态

• 主要的市场成长的推动要素
• 市场成长的课题

第13章 竞争情形

• ADC Therapeutics
• AstraZeneca
• Biocytogen
• Biokin
• Bristol Myers Squibb
• Daiichi Sankyo
• Duality Biologics
• Gilead
• Immunogen
• Innovent Biologics
• Kelun Biotech
• LigaChem Biosciences
• Merck
• Pfizer
• Roche

Global Lung Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price & Clinical Trials Insight 2030 Report Finding & Highlights:

• Research Methodology
• Global Lung Cancer Antibody Drug Conjugates Market Opportunity: > US$ 2 Billion
• Global & Regional Trends Insight
• Commercially Approved Lung Cancer Antibody Drug Conjugates By Brand Name, Company & Indication
• Approved Lung Cancer Antibody Drug Conjugates Patent, Dosage & Price Analysis
• Insight On Lung Cancer Antibody Drug Conjugates In Clinical Trials: > 120 Drug Conjugates
• Lung Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
• Cancer Antibody Drug Conjugates Development Platforms By Company

Need For Antibody Drug Conjugates Lung Cancer Treatment & Why This Report

Lung cancer's high incidence and mortality rates make it one of the most challenging cancers to manage globally. While traditional therapies like surgery, chemotherapy, and radiotherapy have been employed, they often fail to provide long-term results, especially in the case of advanced or metastatic disease. As a result, the demand for more specific, effective therapies has prompted the creation of novel therapies, such as antibody drug conjugates (ADCs), which provide a high potential alternative by fusing the specificity of antibodies with the potent anti-cancer activity of chemotherapy. Antibody drug conjugates are designed to preferentially attack cancer cells, thus reducing harm to normal tissue and lowering systemic toxicity, giving them a huge benefit over traditional treatments. As lung cancer's molecular and genetic intricacies continuing to evolve, ADCs are being viewed as essential to enhancing survival for both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) patients.

This report provides an in-depth analysis of the lung cancer antibody drug conjugates market, giving its stakeholders important information on current clinical trials, innovative technology, and leading players defining this market. It brings to light significant trial outcomes, monitors the advancement of promising drugs, and examines the collaborations that are driving this space.

Lung Cancer Antibody Drug Conjugates Clinical Trials Insight Included In the Report

One of the prominent aspects of the report is its comprehensive discussion of current and finished clinical trials for antibody drug conjugates in lung cancer. The report outlines clinical trial phases, geography, and sponsoring companies, providing a detailed insight into where antibody drug conjugates are in their clinical stage. For example, Ifinatamab Deruxtecan (I-DXd), an antibody drug conjugate that targets B7-H3, is in clinical trials for extensive stage SCLC. The report discusses in detail the purpose of the trial, such as assessing the drug's effect on overall survival and response rates, which can be used for decision making in clinical practice.

Additionally, the report indicates the geographical distribution of these trials, indicating the global nature of antibody drug conjugate development for lung cancer. It also explores the indications under investigation, highlighting which lung cancer subtypes are being addressed by various antibody drug conjugates. The information in the report not only gives trial phase data but also indicates key trial results, giving an accurate snapshot of antibody drug conjugate development in the treatment of lung cancer.

Technology Platforms, Collaborations & Agreements

The success of antibody drug conjugates is largely dependent on the technology platforms utilized to develop and provide such therapies. This analysis gets close to the front-running platforms used by top pharma companies to develop successful antibody drug conjugates against lung cancer. For instance, Daiichi Sankyo's DXd platform is noted for its integration of a cleavable linker, a topoisomerase I inhibitor payload, and a highly active cytotoxic drug. It was responsible for creating Enhertu and Datroway, which have proved effective in HER2- and EGFR-mutated NSCLC.

Moreover, the report investigates increasing partnerships among big pharma companies, like the collaboration between Merck and Daiichi Sankyo for antibody drug conjugate development against immune checkpoint targets like B7-H3 in SCLC. These partnerships are imperative in driving antibody drug conjugates through the clinic and closer to approval. By reviewing these partnerships and tech platforms, the report depicts the advanced strategies driving antibody drug conjugate development clearly.

Major Companies Active In R&D For Lung Cancer Treatment

The report provides a comprehensive analysis of leading pharmaceutical and biotech companies developing antibody drug conjugate based therapy for lung cancer. AstraZeneca, Daiichi Sankyo, Pfizer, and Bristol Myers Squibb are identified as leading companies in developing antibody drug conjugates. The leading companies are developing a pipeline of promising antibody drug conjugates that target different tumor antigens such as HER2, TROP-2, and B7-H3, all of which play an important role in the treatment of lung cancer.

The report highlights these firms for their continued research activities, such as improving the strength and specificity of their antibody drug conjugates. Through profiling these industry leaders, the report sheds light on the competitive dynamics surrounding antibody drug conjugate development and providing insight as to who among these firms are leading the way in lung cancer treatment advancement.

Report Suggesting Future Direction Of Antibody Drug Conjugates Lung Cancer Treatment

Looking forward, the report provides a glimpse into what the future holds for antibody drug conjugates in lung cancer therapy, and how upcoming trends and technologies may define the market. An important area covered is the growing emphasis on combination therapies, whereby antibody drug conjugates are being combined with other therapeutic modalities like immune checkpoint inhibitors and angiogenesis inhibitors. The purpose of this approach is to maximize the therapeutic index of antibody drug conjugates and counter mechanisms of resistance that could develop in patients.

The report also foresees a trend towards more personalized treatment approaches, where antibody drug conjugates are engineered to attack particular genetic mutations or tumor antigens prevalent in individual patients. This is the pattern with clinical trials evaluating Patritumab Deruxtecan, an antibody drug conjugate against HER3, prepared specifically for NSCLC patients harboring particular EGFR mutations. These trends imply that antibody drug conjugates will not only be employed as monotherapies but may instead become part of more comprehensive, multi component treatment protocols.

Through the examination of trends and directions, the report presents a forward looking view of antibody drug conjugates in lung cancer therapy, providing useful advice for interested stakeholders in the field of this fast moving therapeutic area.

Table of Contents

1. Introduction To Lung Cancer Antibody Drug Conjugates

• 1.1 Overview
• 1.2 Mechanism Of Antibody Drug Conjugates

2. Antibody Drug Conjugates As Lung Cancer Targeted Therapy

• 2.1 Applications Of Antibody Drug Conjugates In Lung Cancer
• 2.2 Advantages Of Antibody Drug Conjugates
• 2.3 Comparison Of Antibody Drug Conjugates With Traditional Therapies
• 2.4 Lung Cancer Antibody Drug Conjugates Combination Therapies

3. Generations Of Lung Cancer Antibody Drug Conjugates

• 3.1 Antibody Drug Conjugates - Evolution
• 3.2 Next Generation Antibody Drug Conjugates Prospects

4. Commercially Approved Lung Cancer Antibody Drug Conjugates By Brand Name, Company & Indication

5. Global Lung Cancer Antibody Drug Conjugates Market Outlook

• 5.1 Current Market Scenario
• 5.2 Global Lung Cancer Antibody Drug Conjugates Market Trends & Development
• 5.3 Future Growth Avenues

6. Global Lung Cancer Antibody Drug Conjugates Research & Market Trends by Region

• 6.1 US
• 6.2 China
• 6.3 Europe
• 6.4 Japan
• 6.5 South Korea

7. Approved Lung Cancer Antibody Drug Conjugates - Patent, Dosage & Price Analysis

• 7.1 Enhertu
  • 7.1.1 Overview, Availability & Patent Insight
  • 7.1.2 Pricing & Dosage Insight
• 7.2 Sacituzumab Tirumotecan
  • 7.2.1 Overview, Availability & Patent Insight
• 7.3 Datroway
  • 7.3.1 Overview & Availability Insight
  • 7.3.2 Dosage & Price Analysis
• 7.4 Emrelis
  • 7.4.1 Overview & Availability Insights
  • 7.4.2 Pricing & Dosing Insight
• 7.5 Trastuzumab Rezetecan
  • 7.5.1 Overview & Availability Insight

8. Global Lung Cancer Antibody Drug Conjugates Clinical Trials Overview

• 8.1 By Phase
• 8.2 By Indication
• 8.3 By Company
• 8.4 By Fast Track & Orphan Status
• 8.5 By Country

9. Global Lung Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

• 9.1 Research
• 9.2 Preclinical
• 9.3 Phase I
• 9.4 Phase I/II
• 9.5 Phase II
• 9.6 Phase II/III
• 9.7 Phase III
• 9.8 Registration

10. Marketed Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

11. Cancer Antibody Drug Conjugates Development Platforms By Company

12. Global lung Cancer Antibody Drug Conjugates Market Dynamics

• 12.1 Key Market Growth Drivers
• 12.2 Challenges For Market Growth

13. Competitive Landscape

• 13.1 ADC Therapeutics
• 13.2 AstraZeneca
• 13.3 Biocytogen
• 13.4 Biokin
• 13.5 Bristol Myers Squibb
• 13.6 Daiichi Sankyo
• 13.7 Duality Biologics
• 13.8 Gilead
• 13.9 Immunogen
• 13.10 Innovent Biologics
• 13.11 Kelun Biotech
• 13.12 LigaChem Biosciences
• 13.13 Merck
• 13.14 Pfizer
• 13.15 Roche

List of Figures

• Figure 1-1: Antibody Drug Conjugates - General Working Mechanism
• Figure 2-1: Advantages of Antibody Drug Conjugates
• Figure 2-2: Lung Cancer - Antibody Drug Conjugate Combinations In Studies
• Figure 3-1: Cancer Antibody Drug Conjugates - Opportunities For Next-Generation Development
• Figure 5-1: Global - Lung Cancer Antibody Drug Conjugates Market (US$ Million), 2023-2025
• Figure 5-2: IDeate-Lung02 Phase 3 (NCT06203210) Study - Initiation & Completion Year
• Figure 5-3: SGNB6A-001 Phase 1 (NCT04389632) Study - Initiation & Completion Year
• Figure 5-4: SGNB6A-002 Phase 3 (NCT06012435) Study - Initiation & Completion Year
• Figure 5-5: MK-2870-004 Phase 3 (NCT06074588) Study - Initiation & Completion Year
• Figure 5-6: SHR-4849-101 Phase 1 (NCT06443489) Study - Initiation & Completion Year
• Figure 5-7: Global - Lung Cancer Antibody Drug Conjugate Market Forecast (US$ Million), 2026 - 2030
• Figure 7-1: Enhertu - Cost Of Supply In US & Europe (US$), September'2025
• Figure 7-2: Datroway - Cost Of 100 mg Supply In US & Europe (US$), September'2025
• Figure 7-3: Emrelis - Cost Per Supply (US$), September'2025
• Figure 8-1: Global - Lung Cancer Antibody Drug Conjugate In Clinical Trials By Phase, 2025 Till 2030
• Figure 8-2: Global- Cancer Antibody Drug Conjugate In Clinical Trials By Indication, 2025 Till 2030
• Figure 8-3: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Company, 2025 Till 2030
• Figure 8-4: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Fast Track & Orphan Status, 2025 Till 2030
• Figure 8-5: Global - Cancer Antibody Drug Conjugate In Clinical Pipeline By Country, 2025 Till 2030
• Figure 11-1: Proprietary ADC Technology - Seagen
• Figure 11-2: ALE.P02 & ALE.P03 - Alentis Therapeutics
• Figure 11-3: TRAAC - Tallac Therapeutics
• Figure 11-4: ATAC - Heidelberg Pharma
• Figure 11-5: Tub-tag(R) & P5 - Tubulis

List of Tables

• Table 2-1: Lung Cancer - Antibody Drug Conjugates vs. Traditional Therapies
• Table 2-2: Lung Cancer - Ongoing Antibody Drug Conjugate Combination Clinical Trials
• Table 3-1: Lung Cancer - Approved Second Generation Antibody Drug Conjugates
• Table 3-2: Lung Cancer - Approved Third Generation Antibody Drug Conjugates
• Table 3-3: Lung Cancer - Approved Fourth Generation Antibody Drug Conjugates
• Table 3-4: Lung Cancer - Summary Of Antibody-Drug Conjugate Generations
• Table 4-1: Lung Cancer - Approved Antibody Drug Conjugates, September'2025
• Table 6-1: US - Approved Lung Cancer Antibody Drug Conjugates, September'2025
• Table 6-2: China - Approved Lung Cancer Antibody Drug Conjugates, September'2025
• Table 6-3: EU - Approved Cancer Antibody Drug Conjugates, September'2025
• Table 6-4: Japan - Approved Cancer Antibody Drug Conjugates, September'2025
• Table 7-1: Datroway - Premedication & Concomitant Medications
• Table 7-2: Datroway - Recommended Dosage Reductions For Adverse Reactions
• Table 7-3: Emrelis: Recommended Dose Reductions